Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435153 | 0.99 | AR (0.94) | AR | |
| SCHEMBL31060476 | 0.96 | AR (1.00) | AR | |
| SCHEMBL1435382 | 0.96 | AR (1.00) | AR | |
| SCHEMBL12812119 | 0.93 | AR (0.80) | AR | |
| SCHEMBL1435491 | 0.92 | AR (0.89) | AR | |
| SCHEMBL12812021 | 0.88 | AR (0.75) | AR | |
| SCHEMBL1435321 | 0.86 | AR (0.82) | AR | |
| SCHEMBL5585250 | 0.86 | AR (0.98) | AR | |
| SCHEMBL5585067 | 0.86 | AR (0.98) | AR | |
| SCHEMBL5585121 | 0.86 | AR (0.98) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1775289-B1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-03-30 | — | — | EP | claimed |
| US-7803826-B2 | Imidazolidine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-28 | — | — | US | claimed |
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-25 | — | — | US | claimed |
| EP-1775289-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-04-18 | — | — | EP | claimed |
| EP-1775289-B1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-03-30 | — | — | EP | disclosed |
| EP-1775289-B1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-7803826-B2 | Imidazolidine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7803826-B2 | Imidazolidine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1775289-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1775289-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CYP3A4, CYP4B1, OPRD1 | AR 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.